May 1, 2018 9:31:57 AM / by Paul McGarry
Hackensack, NJ – May 1, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Amy Wesa, Ph.D, has joined the company as Director of Immuno-Oncology Research.
Apr 3, 2018 9:34:28 AM / by Paul McGarry
Hackensack, NJ – April 3, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year’s MicroCap Conference on Tuesday, April 10, 2018 at 9:30am.
Mar 16, 2018 11:50:20 AM / by Paul McGarry
Hackensack, NJ – March 15, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third fiscal quarter and nine months ended January 31, 2018.
Feb 26, 2018 9:15:48 AM / by Paul McGarry
Hackensack, NJ – February 26, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will participate at the 30th Annual Roth Conference and will conduct one-on-one meetings.
Feb 20, 2018 10:38:47 AM / by Paul McGarry
SAN CARLOS, Calif. and Hackensack, NJ (February 20, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX) models for ROS1-fusion driven cancers to understand what drives tumor development, therapeutic response and acquired resistance to enable the development of new and more effective therapies against this under-studied molecular subset of cancer.
Dec 12, 2017 11:08:16 AM / by Mark Weinstein
Hackensack, NJ – December 7, 2017 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second fiscal quarter and six months ended October 31, 2017.
Sep 26, 2017 2:53:02 PM / by Mark Weinstein
HACKENSACK, NJ - September 26, 2017 - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the signing of a competitive contract through the government’s Small Business Innovation Research (SBIR) program. The contract is in response to Topic 355 – Cell and Animal-Based Models to Advance Cancer Ethnic Health Disparity Research. Champions’ direct-to-Phase II proposal, entitled “Metastatic Prostate Cancer Patient Derived Xenograft Modeling; A New Operating Paradigm”. The contract is a 2-year, $2 million project. Champions’ network of collaborating sites will contribute to this project.
Sep 18, 2017 8:42:51 AM / by Mark Weinstein
HACKENSACK, NJ - September 18, 2017 - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the publication entitled “Patient-derived xenografts (PDX) effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors” in the journal Annals of Oncology. Annals of Oncology is published by the European Society for Medical oncology (ESMO), the leading European professional organization for medical oncology in Europe. Building on earlier clinical correlation data, this study further demonstrates that PDX models accurately predict patient response to oncology drugs with remarkable 85% positive predictive value.
Sep 15, 2017 12:37:57 PM / by Mark Weinstein
Hackensack, NJ – September 14, 2017 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2017.
Aug 21, 2017 1:22:51 PM / by Mark Weinstein
HACKENSACK, NJ - August 21, 2017 /PRNewswire/ - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These models will be used in AstraZeneca’s oncology R&D programs in breast and lung cancer, in addition to being added to Champions’ existing TumorGraft bank for translational oncology research for academic and industry customers. Champions’ global network of collaborating sites will be leveraged to support this multi-year initiative.
Champions Oncology has been attentively monitoring the impact of the novel Coronavirus (Covid-19) on our daily internal operations. Our priority is the well-being of our employees and the animals in our care, while also ensuring everyone stays healthy. Champions Oncology is working to manage the potential impact of the situation on our business and also ensure continuity to our customers externally. Our Executive Leadership Team is meeting frequently to evaluate the global circumstances and provide information and resources needed to manage the situation within our company as effectively as possible. Here are some actions that we are taking now to mitigate the effects on our business and in turn, to you our customers:
Operations:
Human Resources: